Gajra, Ajeet http://orcid.org/0000-0002-5929-0466
Zalenski, Abigail http://orcid.org/0000-0002-9541-6513
Sannareddy, Aishwarya
Jeune-Smith, Yolaine http://orcid.org/0000-0002-1711-849X
Kapinos, Kandice http://orcid.org/0000-0003-1577-4917
Kansagra, Ankit http://orcid.org/0000-0001-6901-0782
Article History
Accepted: 1 April 2022
First Online: 7 June 2022
Declarations
:
: Open access publication was funded by Cardinal Health. No external funding was used in the preparation of this article.
: Ajeet Gajra is a Cardinal Health employee, owns Cardinal Health stock, and is an employee of ICON Clinical Research. Abigail Zalenski is a Cardinal Health employee. Yolaine Jeune-Smith is a Cardinal Health employee and owns Cardinal Health stock. Ankit Kansagra is on the advisory board for AbbVie, Alynylam<sup>®</sup> Pharmaceuticals, Bristol Myers Squibb, Cota Healthcare, GlaxoSmithKline, Janssen Pharmaceuticals, Oncopeptides, and Takeda. Aishwarya Sannareddy and Kandice Kapinos declare that they have no conflicts of interest that might be relevant to the contents of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All of the authors (AG, AAZ, AS, YJS, KK, and AK) participated in writing and review of the manuscript. AG and AK were responsible for conceptualization of the manuscript. All authors have read and approved the final version.